Leadership team

Mark has been a leader in the Urology industry for over 36 years. He has introduced 5 new products into the market that have become the standard of care. He has been a Director of another Pharma start-up for 5 years, which is commencing FDA trials. He is a change agent.

Emeritus Consultant Surgeon. Multi-International awarded, research orientated projects. Doctorate in Medicine 2012 and RACS Medalist in 2019.

Commenced the unique scientific investigations of Photodynamic Therapy. Continuing with PDT research, including Immunotherapy in association with the Monash Hudson Institute. The aim is to introduce Immuno-Photodynamic Therapy, to mainstream Prostate Cancer management.

Hon has extensive operational and financial expertise in diverse corporate segments, combined with his tenure at listed and private companies, which brings invaluable financial acumen and experience.  His AI expertise is critical to future success.

President of the SIU, a 17600 Urologist member organisation from 141 countries.

Honorary Fellow of the Edinborough Society of Urologists for his contribution to Urology Education

Richard has extensive national and international experience in cancer drug development, clinical strategy, technical diligence, IP capture and international regulatory affairs. Over the past 25 years he has worked with large pharma such as Bristol Myers Squibb and Eli Lilly & Company and as CEO and CSO for listed, startup and private biotech companies.